Atlas stumbled: Kinesin light chain-1 variant E triggers a vicious cycle of axonal transport disruption and amyloid-β generation in Alzheimer's disease

BioEssays

Volumn 37, Issue 2, 2015, Pages 131-141

  Gan, Kathlyn J ^a   Morihara, Takashi ^b   Silverman, Michael A ^a,c  

^a SIMON FRASER UNIVERSITY   (Canada)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alternative splicing; Alzheimer's disease; Amyloid precursor protein; Amyloid ; Axonal transport; Kinesin; Kinesin light chain

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; KINESIN; KINESIN LIGHT CHAIN 1 VARIANT E; UNCLASSIFIED DRUG; KINESIN LIGHT-CHAIN PROTEINS; MICROTUBULE ASSOCIATED PROTEIN;

ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; BINDING AFFINITY; CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; GENETIC SCREENING; HUMAN; NERVE FIBER TRANSPORT; NONHUMAN; NOTE; PROTEIN PROCESSING; SECRETORY PATHWAY; ANIMAL; GENETICS; METABOLISM; PHYSIOLOGY;

ALTERNATIVE SPLICING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AXONAL TRANSPORT; HUMANS; KINESIN; MICROTUBULE-ASSOCIATED PROTEINS;

EID: 84921533773     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201400131     Document Type: Note

References (119)

1. Craig AM, Banker G. 1994. Neuronal polarity. Annu Rev Neurosci 17: 267-310.
2. Arimura N, Kaibuchi K. 2007. Neuronal polarity: from extracellular signals to intracellular mechanisms. Nat Rev Neurosci 8: 194-205.
3. Hinckelmann MV, Zala D, Saudou F. 2013. Releasing the brake: restoring fast axonal transport in neurodegenerative disorders. Trends Cell Biol 23: 634-43.
4. Millecamps S, Julien JP. 2013. Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci 14: 161-76.
5. Fu MM, Holzbaur EL. 2014. Integrated regulation of motor-driven organelle transport by scaffolding proteins. Trends Cell Biol 24: 564-74.
6. Fang C, Decker H, Banker G. 2014. Axonal transport plays a crucial role in mediating the axon-protective effects of NmNAT. Neurobiol Dis 68: 78-90.
7. Goldstein LS. 2012. Axonal transport and neurodegenerative disease: can we see the elephant? Prog Neurobiol 99: 186-90.
8. Terry RD. 1998. The cytoskeleton in Alzheimer disease. J Neural Transm Suppl 53: 141-5.
9. Lazarov O, Morfini GA, Pigino G, Gadadhar A, et al. 2007. Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J Neurosci 27: 7011-20.
10. Twelvetrees AE, Yuen EY, Arancibia-Carcamo IL, MacAskill AF, et al. 2010. Delivery of GABAARs to synapses is mediated by HAP1-KIF5 and disrupted by mutant huntingtin. Neuron 65: 53-65.
11. Farrer MJ, Hulihan MM, Kachergus JM, Dachsel JC, et al. 2009. DCTN1 mutations in Perry syndrome. Nat Genet 41: 163-5.
12. Dumanchin C, Camuzat A, Campion D, Verpillat P, et al. 1998. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum Mol Genet 7: 1825-9.
13. Jiang S, Li Y, Zhang X, Bu G, et al. 2014. Trafficking regulation of proteins in Alzheimer's disease. Mol Neurodegener 9: 6.
14. Zhang S, Zhang M, Cai F, Song W. 2013. Biological function of Presenilin and its role in AD pathogenesis. Transl Neurodegener 2: 15.
15. Citron M, Westaway D, Xia W, Carlson G, et al. 1997. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3: 67-72.
16. De Felice FG, Wu D, Lambert MP, Fernandez SJ, et al. 2008. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 29: 1334-47.
17. Morris M, Maeda S, Vossel K, Mucke L. 2011. The many faces of tau. Neuron 70: 410-26.
18. Reifert J, Hartung-Cranston D, Feinstein SC. 2011. Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau phosphorylation. J Biol Chem 286: 20797-811.
19. Stokin GB, Goldstein LS. 2006. Axonal transport and Alzheimer's disease. Annu Rev Biochem 75: 607-27.
20. Morfini GA, Burns M, Binder LI, Kanaan NM, et al. 2009. Axonal transport defects in neurodegenerative diseases. J Neurosci 29: 12776-86.
21. Mandelkow EM, Stamer K, Vogel R, Thies E, et al. 2003. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24: 1079-85.
22. LaPointe NE, Morfini G, Pigino G, Gaisina IN, et al. 2009. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res 87: 440-51.
23. Kanaan NM, Morfini GA, LaPointe NE, Pigino GF, et al. 2011. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J Neurosci 31: 9858-68.
24. Ramser EM, Gan KJ, Decker H, Fan EY, et al. 2013. Amyloid-beta oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons. Mol Biol Cell 24: 2494-505.
25. Pigino G, Morfini G, Pelsman A, Mattson MP, et al. 2003. Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci 23: 4499-508.
26. Stokin GB, Almenar-Queralt A, Gunawardena S, Rodrigues EM, et al. 2008. Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides. Hum Mol Genet 17: 3474-86.
27. Rodrigues EM, Weissmiller AM, Goldstein LS. 2012. Enhanced beta-secretase processing alters APP axonal transport and leads to axonal defects. Hum Mol Genet 21: 4587-601.
28. Minoshima S, Cross D. 2008. In vivo imaging of axonal transport using MRI: aging and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35: S89-92.
29. Gallagher JJ, Zhang X, Ziomek GJ, Jacobs RE, et al. 2012. Deficits in axonal transport in hippocampal-based circuitry and the visual pathway in APP knock-out animals witnessed by manganese enhanced MRI. Neuroimage 60: 1856-66.
30. Stokin GB, Lillo C, Falzone TL, Brusch RG, et al. 2005. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 1282-8.
31. Morihara T, Hayashi N, Yokokoji M, Akatsu H, et al. 2014. Transcriptome analysis of distinct mouse strains reveals kinesin light chain-1 splicing as an amyloid-beta accumulation modifier. Proc Natl Acad Sci USA 111: 2638-43.
32. Lawrence CJ, Dawe RK, Christie KR, Cleveland DW, et al. 2004. A standardized kinesin nomenclature. J Cell Biol 167: 19-22.
33. Hirokawa N, Niwa S, Tanaka Y. 2010. Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. Neuron 68: 610-38.
34. Miki H, Setou M, Kaneshiro K, Hirokawa N. 2001. All kinesin superfamily protein, KIF, genes in mouse and human. Proc Natl Acad Sci USA 98: 7004-11.
35. Maeder CI, Shen K, Hoogenraad CC. 2014. Axon and dendritic trafficking. Curr Opin Neurobiol 27C: 165-70.
36. Franker MA, Hoogenraad CC. 2013. Microtubule-based transport - basic mechanisms, traffic rules and role in neurological pathogenesis. J Cell Sci 126: 2319-29.
37. Bloom GS, Wagner MC, Pfister KK, Brady ST. 1988. Native structure and physical properties of bovine brain kinesin and identification of the ATP-binding subunit polypeptide. Biochemistry 27: 3409-16.
38. Kanai Y, Okada Y, Tanaka Y, Harada A, et al. 2000. KIF5C, a novel neuronal kinesin enriched in motor neurons. J Neurosci 20: 6374-84.
39. Niclas J, Navone F, Hom-Booher N, Vale RD. 1994. Cloning and localization of a conventional kinesin motor expressed exclusively in neurons. Neuron 12: 1059-72.
40. Wong YL, Rice SE. 2010. Kinesin's light chains inhibit the head- and microtubule-binding activity of its tail. Proc Natl Acad Sci USA 107: 11781-6.
41. Dietrich KA, Sindelar CV, Brewer PD, Downing KH, et al. 2008. The kinesin-1 motor protein is regulated by a direct interaction of its head and tail. Proc Natl Acad Sci USA 105: 8938-43.
42. Kaan HY, Hackney DD, Kozielski F. 2011. The structure of the kinesin-1 motor-tail complex reveals the mechanism of autoinhibition. Science 333: 883-5.
43. Gyoeva FK, Sarkisov DV, Khodjakov AL, Minin AA. 2004. The tetrameric molecule of conventional kinesin contains identical light chains. Biochemistry 43: 13525-31.
44. Diefenbach RJ, Mackay JP, Armati PJ, Cunningham AL. 1998. The C-terminal region of the stalk domain of ubiquitous human kinesin heavy chain contains the binding site for kinesin light chain. Biochemistry 37: 16663-70.
45. Stenoien DL, Brady ST. 1997. Immunochemical analysis of kinesin light chain function. Mol Biol Cell 8: 675-89.
46. Gindhart JG, Jr., Desai CJ, Beushausen S, Zinn K, et al. 1998. Kinesin light chains are essential for axonal transport in Drosophila. J Cell Biol 141: 443-54.
47. Verhey KJ, Meyer D, Deehan R, Blenis J, et al. 2001. Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J Cell Biol 152: 959-70.
48. Pernigo S, Lamprecht A, Steiner RA, Dodding MP. 2013. Structural basis for kinesin-1:cargo recognition. Science 340: 356-9.
49. McCart AE, Mahony D, Rothnagel JA. 2003. Alternatively spliced products of the human kinesin light chain 1 (KNS2) gene. Traffic 4: 576-80.
50. Khodjakov A, Lizunova EM, Minin AA, Koonce MP, et al. 1998. A specific light chain of kinesin associates with mitochondria in cultured cells. Mol Biol Cell 9: 333-43.
51. Wozniak MJ, Allan VJ. 2006. Cargo selection by specific kinesin light chain 1 isoforms. EMBO J 25: 5457-68.
52. Gyoeva FK, Bybikova EM, Minin AA. 2000. An isoform of kinesin light chain specific for the Golgi complex. J Cell Sci 113: 2047-54.
53. Dikeakos JD, Di Lello P, Lacombe MJ, Ghirlando R, et al. 2009. Functional and structural characterization of a dense core secretory granule sorting domain from the PC1/3 protease. Proc Natl Acad Sci USA 106: 7408-13.
54. Duncan RR, Greaves J, Wiegand UK, Matskevich I, et al. 2003. Functional and spatial segregation of secretory vesicle pools according to vesicle age. Nature 422: 176-80.
55. Handley MT, Haynes LP, Burgoyne RD. 2007. Differential dynamics of Rab3A and Rab27A on secretory granules. J Cell Sci 120: 973-84.
56. Kuliawat R, Arvan P. 1994. Distinct molecular mechanisms for protein sorting within immature secretory granules of pancreatic beta-cells. J Cell Biol 126: 77-86.
57. Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, et al. 2001. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 414: 643-8.
58. Kamal A, Stokin GB, Yang Z, Xia CH, et al. 2000. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 28: 449-59.
59. Blasius TL, Cai D, Jih GT, Toret CP, et al. 2007. Two binding partners cooperate to activate the molecular motor Kinesin-1. J Cell Biol 176: 11-7.
60. Lazarov O, Morfini GA, Lee EB, Farah MH, et al. 2005. Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. J Neurosci 25: 2386-95.
61. Das U, Scott DA, Ganguly A, Koo EH, et al. 2013. Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron 79: 447-60.
62. Fu MM, Holzbaur EL. 2013. JIP1 regulates the directionality of APP axonal transport by coordinating kinesin and dynein motors. J Cell Biol 202: 495-508.
63. Killian RL, Flippin JD, Herrera CM, Almenar-Queralt A, et al. 2012. Kinesin light chain 1 suppression impairs human embryonic stem cell neural differentiation and amyloid precursor protein metabolism. PLoS One 7: e29755.
64. Chyung AS, Greenberg BD, Cook DG, Doms RW, et al. 1997. Novel beta-secretase cleavage of beta-amyloid precursor protein in the endoplasmic reticulum/intermediate compartment of NT2N cells. J Cell Biol 138: 671-80.
65. Walter J, Capell A, Grunberg J, Pesold B, et al. 1996. The Alzheimer's disease-associated presenilins are differentially phosphorylated proteins located predominantly within the endoplasmic reticulum. Mol Med 2: 673-91.
66. Muresan V, Muresan Z. 2012. A persistent stress response to impeded axonal transport leads to accumulation of amyloid-beta in the endoplasmic reticulum, and is a probable cause of sporadic Alzheimer's disease. Neurodegener Dis 10: 60-3.
67. Muresan Z, Muresan V. 2005. Coordinated transport of phosphorylated amyloid-beta precursor protein and c-Jun NH2-terminal kinase-interacting protein-1. J Cell Biol 171: 615-25.
68. Muresan V, Varvel NH, Lamb BT, Muresan Z. 2009. The cleavage products of amyloid-beta precursor protein are sorted to distinct carrier vesicles that are independently transported within neurites. J Neurosci 29: 3565-78.
69. Placido AI, Pereira CM, Duarte AI, Candeias E, et al. 2014. The role of endoplasmic reticulum in amyloid precursor protein processing and trafficking: implications for Alzheimer's disease. Biochim Biophys Acta 1842: 1444-53.
70. Li JQ, Yu JT, Jiang T, Tan L. 2014. Endoplasmic reticulum dysfunction in Alzheimer's disease. Mol Neurobiol, in press, doi 10.1007/s12035-014-8695-8.
71. Marzolo MP, Bu G. 2009. Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. Semin Cell Dev Biol 20: 191-200.
72. Holtzman DM, Herz J, Bu G. 2012. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2: a006312.
73. Fuentealba RA, Barria MI, Lee J, Cam J, et al. 2007. ApoER2 expression increases Abeta production while decreasing Amyloid Precursor Protein (APP) endocytosis: possible role in the partitioning of APP into lipid rafts and in the regulation of gamma-secretase activity. Mol Neurodegener 2: 14.
74. Vagnoni A, Perkinton MS, Gray EH, Francis PT, et al. 2012. Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates Abeta production. Hum Mol Genet 21: 2845-54.
75. Ludwig A, Blume J, Diep TM, Yuan J, et al. 2009. Calsyntenins mediate TGN exit of APP in a kinesin-1-dependent manner. Traffic 10: 572-89.
76. Steuble M, Diep TM, Schatzle P, Ludwig A, et al. 2012. Calsyntenin-1 shelters APP from proteolytic processing during anterograde axonal transport. Biol Open 1: 761-74.
77. Ikonomov OC, Fligger J, Sbrissa D, Dondapati R, et al. 2009. Kinesin adapter JLP links PIKfyve to microtubule-based endosome-to-trans-Golgi network traffic of furin. J Biol Chem 284: 3750-61.
78. Hwang EM, Kim SK, Sohn JH, Lee JY, et al. 2006. Furin is an endogenous regulator of alpha-secretase associated APP processing. Biochem Biophys Res Commun 349: 654-9.
79. LaFerla FM, Green KN, Oddo S. 2007. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8: 499-509.
80. Pagani L, Eckert A. 2011. Amyloid-Beta interaction with mitochondria. Int J Alzheimers Dis 2011: 925050.
81. Kudo T, Okumura M, Imaizumi K, Araki W, et al. 2006. Altered localization of amyloid precursor protein under endoplasmic reticulum stress. Biochem Biophys Res Commun 344: 525-30.
82. Querfurth HW, LaFerla FM. 2010. Alzheimer's disease. N Engl J Med 362: 329-44.
83. Yan Y, Wang C. 2007. Abeta40 protects non-toxic Abeta42 monomer from aggregation. J Mol Biol 369: 909-16.
84. Jan A, Gokce O, Luthi-Carter R, Lashuel HA. 2008. The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J Biol Chem 283: 28176-89.
85. Zou K, Kim D, Kakio A, Byun K, et al. 2003. Amyloid beta-protein (Abeta) 1-40 protects neurons from damage induced by Abeta 1-42 in culture and in rat brain. J Neurochem 87: 609-19.
86. Puzzo D, Privitera L, Leznik E, Fa M, et al. 2008. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28: 14537-45.
87. Puzzo D, Privitera L, Fa M, Staniszewski A, et al. 2011. Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 69: 819-30.
88. Herrup K. 2010. Reimagining Alzheimer's disease - an age-based hypothesis. J Neurosci 30: 16755-62.
89. Benilova I, Karran E, De Strooper B. 2012. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15: 349-57.
90. Ferreira ST, Klein WL. 2011. The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem 96: 529-43.
91. Borysov SI, Granic A, Padmanabhan J, Walczak CE, et al. 2011. Alzheimer Abeta disrupts the mitotic spindle and directly inhibits mitotic microtubule motors. Cell Cycle 10: 1397-410.
92. Ari C, Borysov SI, Wu J, Padmanabhan J, et al. 2014. Alzheimer amyloid beta inhibition of Eg5/kinesin 5 reduces neurotrophin and/or transmitter receptor function. Neurobiol Aging 35: 1839-49.
93. Medina M, Avila J. 2014. New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. Expert Opin Ther Targets 18: 69-77.
94. Ly PT, Wu Y, Zou H, Wang R, et al. 2013. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 123: 224-35.
95. Twomey C, McCarthy JV. 2006. Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate. FEBS Lett 580: 4015-20.
96. Aplin AE, Jacobsen JS, Anderton BH, Gallo JM. 1997. Effect of increased glycogen synthase kinase-3 activity upon the maturation of the amyloid precursor protein in transfected cells. Neuroreport 8: 639-43.
97. Aplin AE, Gibb GM, Jacobsen JS, Gallo JM, et al. 1996. In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J Neurochem 67: 699-707.
98. Weaver C, Leidel C, Szpankowski L, Farley NM, et al. 2013. Endogenous GSK-3/shaggy regulates bidirectional axonal transport of the amyloid precursor protein. Traffic 14: 295-308.
99. Morfini G, Szebenyi G, Elluru R, Ratner N, et al. 2002. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. Embo J 21: 281-93.
100. Shaw JL, Chang KT. 2013. Nebula/DSCR1 upregulation delays neurodegeneration and protects against APP-induced axonal transport defects by restoring calcineurin and GSK-3beta signaling. PLoS Genet 9: e1003792.
101. Kimberly WT, Zheng JB, Town T, Flavell RA, et al. 2005. Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J Neurosci 25: 5533-43.
102. Colombo A, Bastone A, Ploia C, Sclip A, et al. 2009. JNK regulates APP cleavage and degradation in a model of Alzheimer's disease. Neurobiol Dis 33: 518-25.
103. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, et al. 2012. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 122: 1339-53.
104. Horiuchi D, Collins CA, Bhat P, Barkus RV, et al. 2007. Control of a kinesin-cargo linkage mechanism by JNK pathway kinases. Curr Biol 17: 1313-7.
105. Pimenova AA, Thathiah A, De Strooper B, Tesseur I. 2014. Regulation of amyloid precursor protein processing by serotonin signaling. PLoS One, 9: e87014.
106. Pigino G, Morfini G, Atagi Y, Deshpande A, et al. 2009. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc Natl Acad Sci USA 106: 5907-12.
107. Perez DI, Gil C, Martinez A. 2011. Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Med Res Rev 31: 924-54.
108. Iijima K, Ando K, Takeda S, Satoh Y, et al. 2000. Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. J Neurochem 75: 1085-91.
109. Lee MS, Kao SC, Lemere CA, Xia W, et al. 2003. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163: 83-95.
110. Lee S, Sunil N, Shea TB. 2011. C-terminal neurofilament phosphorylation fosters neurofilament-neurofilament associations that compete with axonal transport. Cytoskeleton (Hoboken) 68: 8-17.
111. Morfini G, Szebenyi G, Brown H, Pant HC, et al. 2004. A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J 23: 2235-45.
112. Bracale A, Cesca F, Neubrand VE, Newsome TP, et al. 2007. Kidins220/ARMS is transported by a kinesin-1-based mechanism likely to be involved in neuronal differentiation. Mol Biol Cell 18: 142-52.
113. Zhu H, Lee HY, Tong Y, Hong BS, et al. 2012. Crystal structures of the tetratricopeptide repeat domains of kinesin light chains: insight into cargo recognition mechanisms. PLoS One 7: e33943.
114. Vagnoni A, Rodriguez L, Manser C, De Vos KJ, et al. 2011. Phosphorylation of kinesin light chain 1 at serine 460 modulates binding and trafficking of calsyntenin-1. J Cell Sci 124: 1032-42.
115. Hammond JW, Blasius TL, Soppina V, Cai D, et al. 2010. Autoinhibition of the kinesin-2 motor KIF17 via dual intramolecular mechanisms. J Cell Biol 189: 1013-25.
116. Cai D, Hoppe AD, Swanson JA, Verhey KJ. 2007. Kinesin-1 structural organization and conformational changes revealed by FRET stoichiometry in live cells. J Cell Biol 176: 51-63.
117. Inoue T, Majid T, Pautler RG. 2011. Manganese enhanced MRI (MEMRI): neurophysiological applications. Rev Neurosci 22: 675-94.
118. Kavanagh T, Mills JD, Kim WS, Halliday GM, et al. 2013. Pathway analysis of the human brain transcriptome in disease. J Mol Neurosci 51: 28-36.
119. Tanahashi H, Tabira T. 2001. Three novel alternatively spliced isoforms of the human beta-site amyloid precursor protein cleaving enzyme (BACE) and their effect on amyloid beta-peptide production. Neurosci Lett 307: 9-12.